High FLT3 expression increases immune‐cell infiltration in the tumor microenvironment and correlates with prolonged disease‐free survival in patients with non‐small cell lung cancer
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Łukasz Kuncman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, Medical University of Lodz, Poland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, fms-Like Tyrosine Kinase 3, Lung Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Most of the currently used cancer immunotherapies inhibit the programmed cell death protein 1 (PD1)–programmed cell death 1 ligand 1 (PDL1) axis of T‐cells. However, dendritic cells (DCs) controlled by natural killer (NK) cells via the FMS‐related tyrosine kinase 3 (FLT3) axis are necessary for activation of T‐cells. The aim of the study was to evaluate FLT3 as a prognostic factor and determine its role in immune infiltration (with emphasis on NK cells and DCs). Using The Cancer Genome Atlas (TCGA) database, we performed bioinformatic analysis of the gene expression datasets of 501 lung squamous cell carcinoma (LUSC) and 515 lung adenocarcinoma (LUAD) patient who had corresponding clinical data [analysis was performed in R (version 4.2.0)]. Disease‐free survival (DFS) differed between the FLT3 ‐low and FLT3 ‐high expression groups, respectively, in LUSC (61.0 vs 71.3 months P = 0.075) and LUAD (32.7 vs 47.5 months P = 0.045). A tumor microenvironment (TME) with high immune infiltration and rich in T‐cell exhaustion markers was observed in the FLT3 ‐high group. We showed overexpression of NK cell and DC gene signatures in the FLT3 ‐high expression group as well as overexpression of key effector genes of the cyclic GMP‐AMP synthase (cGAS)–stimulator of interferon genes protein (STING) pathway, which is crucial in response to radiotherapy. High expression of FLT3 in the TME was associated with immune cell infiltration (especially of NK cells and DCs), increased expression of T‐cell exhaustion markers and expression of effector genes of the cGAS‐STING pathway, which may consequently increase susceptibility to immunotherapy and radiotherapy. High FLT3 expression correlated with prolonged DFS in the LUSC and LUAD cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiotherapy, Medical University of Lodz, Poland.
- Department of External Beam Radiotherapy, Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology, Łódź, Poland.
- Department of Molecular Carcinogenesis, Medical University of Lodz, Poland.
- Department of Urology, Poznan University of Medical Sciences, Poland.
- Department of Genitourinary Oncology, The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland.
ORCID-Profile: Łukasz Kuncman, Magdalena Orzechowska
Zitieren
APA
Kuncman, Ł., Orzechowska, M., Milecki, T., Kucharz, J., & Fijuth, J. (2024). High FLT3 expression increases immune‐cell infiltration in the tumor microenvironment and correlates with prolonged disease‐free survival in patients with non‐small cell lung cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13597
Vancouver
Kuncman Ł, Orzechowska M, Milecki T, Kucharz J, Fijuth J. High FLT3 expression increases immune‐cell infiltration in the tumor microenvironment and correlates with prolonged disease‐free survival in patients with non‐small cell lung cancer. Molecular Oncology. 2024. doi:10.1002/1878-0261.13597
BibTeX
@article{Kuncman2024,
author = {Kuncman, Łukasz and Orzechowska, Magdalena and Milecki, Tomasz and Kucharz, Jakub and Fijuth, Jacek},
title = {High FLT3 expression increases immune‐cell infiltration in the tumor microenvironment and correlates with prolonged disease‐free survival in patients with non‐small cell lung cancer},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13597}
}
EUVIMED